CClinicalTrials.gg
Active, not recruitingNCT07661914Updated Jun 22, 2026

AI_Colonoscopy_for_Fellows

An interventional study of AI assisted colonoscopy and Conventional Colonoscopy in AI-assisted Colonoscopy, sponsored by University of Oklahoma. Active, not recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by University of Oklahoma · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Randomized
Sex
All
01

Study summary

The goal of this study is to look at how good artificial intelligence (AI) assisted colonoscopy is compared to conventional colonoscopy in detecting polyps when used by gastroenterology fellows. The main question the study aims to answer are:

Does AI assisted colonoscopy improve adenoma detection rate for gastroenterology fellows in different levels of training? Does AI assisted colonoscopy improve other quality indicators such as sessile serrated lesion detection rate withdrawal time? This research will compare these quality measures for gastroenterology fellows in their first, second, and third year of training. The gastroenterology fellows performing colonoscopies will be randomized to either AI assisted colonoscopy or conventional colonoscopy for each case. The nurse in the room will then turn on the AI device if needed and the rest of the colonoscopy will be completed as normal. The procedure notes will indicated whether AI device was used or not during the procedure.

Read the detailed description

The proposed study is a randomized controlled trial to evaluate the efficacy of AI assisted colonoscopies in improving colonoscopy quality indices for gastroenterology fellows.

The subjects for this study will be the gastroenterology fellows in their first, second or third year of training. Each fellow during their VA endoscopy rotation will be randomized to perform colonoscopies using AI or following conventional methods. If randomized to AI, the endoscopy technician in the procedural room will be responsible for turning on the GI Genius software (Medtronic AI device) during the procedure. The fellow will identify whether AI was used in the procedural note documented under Provation MD software. Otherwise, all colonoscopies will be performed in the standard fashion under moderate sedation or monitored anesthesia care. Procedures will not be affected by study participation. All procedures will be performed at the Oklahoma City VA Medical Center during normal procedural times. Information such as indication for the procedure and quality indices mentioned above (such as ADR, SSLDR, withdrawal time) will be obtained from chart review and calculated using data from Provation MD retrospectively, at a later time. Other information such as patient's medical history and family history as it relates to the colonoscopy procedure will also be collected retrospectively from CPRS chart records. This will be used to exclude patients undergoing colonoscopy secondary to genetic cancer syndromes (ex: polyposis), inflammatory bowel disease, for therapy of known neoplasms or undergoing non-colonoscopy screening tests (fecal immunochemical test, CT colonography) from this study. No identifiable patient information will be saved in any format. In addition, data such as polyp size, location of polyp and histological information will be collected from CPRS charts.

02

Conditions studied

  • AI-assisted Colonoscopy

Keywords

  • AI assisted colonoscopy
  • GI Genius
03

In context

Lead sponsor

University of Oklahoma is the lead sponsor of 424 studies on the registry; 99 are open to participants now.

Of its 42 completed or terminated interventional studies of FDA-regulated products, 16 (38%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • All adult gastroenterology fellows at the University of Oklahoma, except for the fellow conducting research will be included in the study.

Exclusion criteria

Exclusion Criteria:

  • All patients undergoing colonoscopy for genetic cancer syndromes (ex: polyposis), inflammatory bowel disease, for therapy of known neoplasms or undergoing non-colonoscopy screening tests (fecal immunochemical test, CT colonography) will be excluded from this study.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    AI assisted colonoscopy

    GI fellows in this arm will complete colonoscopies with the assistance of AI device GI Genius.

    Device: AI assisted colonoscopy

  • Active comparator
    Conventional colonoscopy

    GI fellows in this arm will complete colonoscopy in a conventional manner

    Other: Conventional Colonoscopy

Interventions

  • DeviceAI assisted colonoscopy

    The gastroenterology fellows assigned to AI assisted colonoscopy will use the GI genius device while performing colonoscopies.

  • OtherConventional Colonoscopy

    The gastroenterology fellows assigned to conventional colonoscopy will be performing colonoscopies without the use of AI device.

06

What researchers measure

Primary outcomes

  1. Adenoma detection rate

    We hypothesize that an AI assisted colonoscopy done by a gastroenterology fellow will have a higher ADR as compared to conventional colonoscopy done by the same fellow and these results will be more significant among junior fellows compared to senior fellows.

    Time frame: over 18 months

Secondary outcomes

  1. Sessile serrated lesion detection rate

    We hypothesize that an AI assisted colonoscopy done by a gastroenterology fellow will have a higher sessile serrated lesion detection rate as compared to conventional colonoscopy done by the same fellow and these results will be more significant among junior fellows compared to senior fellow.

    Time frame: Over 18 months

  2. Withdrawal time

    Total withdrawal time will likely be longer in the AI assisted colonoscopy group compared to conventional colonoscopy group.

    Time frame: Over 18 months

07

Study locations

1 site
  • Oklahoma City VA Health Care System
    Oklahoma City, Oklahoma 73104, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07661914
Lead sponsor
University of Oklahoma
Collaborators
Oklahoma City VA Medical Center
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
Apr 1, 2026
Primary completion
Mar 30, 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Jun 22, 2026

Study contacts

Mohammad Madhoun
principal investigator · University of Oklahoma

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion